FDA Presents Its Case for Targeting Talc

Your editorial “The FDA Takes a Trial-Lawyer Turn” (May 21) criticizes the Food and Drug Administration for convening an expert panel to explore whether talc is a potential carcinogen…

Your editorial “The FDA Takes a Trial-Lawyer Turn” (May 21) criticizes the Food and Drug Administration for convening an expert panel to explore whether talc is a potential carcinogen…
Read More

About Author

Christeen Mcnaught

See author's posts

FDA Presents Its Case for Targeting Talc

About Author

Christeen Mcnaught

Nerbio’s iTOF® Receives FDA Clearance as First App-Controlled Neuromuscular Blockade Monitor

Diabetes drug shows benefits for patients with liver disease

Baby’s microbiome may protect against later childhood viral infection

Nerbio’s iTOF® Receives FDA Clearance as First App-Controlled Neuromuscular Blockade Monitor

EC approves Santen’s Ryjunea to slow progression of paediatric myopia

Linear Diagnostics awarded £1m to develop rapid STI test

P2Y12 drugs may be better than aspirin to prevent heart attack and stroke in patients with coronary artery disease

Baby’s microbiome may protect against later childhood viral infection

From Tiffany earrings to mobile phones—this is what happens when you swallow something you shouldn’t

Silence Won’t Save Science

Shingles is awful, but here’s another reason to get vaccinated: It may fight dementia

US sees third measles-related death amid outbreaks

Research on multiple sclerosis wins ‘Oscars of science’

Nerbio’s iTOF® Receives FDA Clearance as First App-Controlled Neuromuscular Blockade Monitor

EC approves Santen’s Ryjunea to slow progression of paediatric myopia

Linear Diagnostics awarded £1m to develop rapid STI test

P2Y12 drugs may be better than aspirin to prevent heart attack and stroke in patients with coronary artery disease

Baby’s microbiome may protect against later childhood viral infection

About PhaMed

Recent News

About Author

More Stories

You may have missed

About PhaMed

Recent News

Categories